JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly to $400 from $380 and keeps an Overweight rating on the shares. The analyst sees "encouraging" core product and pipeline traction.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
